Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor,approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
Indicated for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test
Also indicated for metastatic NSCLC tumors that are ROS1-positive
Select patients for treatment of metastatic NSCLC based on presence of ALK or ROS1 positivity in tumor specimens
250 mg orally twice a day
Use: metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive
